Trulicity (dulaglutide) tracker
Educational reference for Trulicity (dulaglutide). Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
120 h
Tmax
48 h
Category
glp1
> PLACEHOLDER — pending clinical review by licensed pharmacist. Trulicity is an FDA-approved dulaglutide brand for type 2 diabetes. Subcutaneous injection.
Mechanism
Trulicity is a brand name for dulaglutide, a long-acting GLP-1 receptor agonist. See the dulaglutide entry for the full mechanism.
Research summary
Trulicity is the once-weekly dulaglutide product approved for type 2 diabetes (AWARD program; cardiovascular outcomes in REWIND). See the dulaglutide entry.
Dosing in the literature
Regimens are individualized and set by a prescribing clinician; they are outside the scope of this summary. See the dulaglutide entry.
Reported side effects
As a dulaglutide product, gastrointestinal effects are most commonly reported; prescribing information includes class warnings. See the dulaglutide entry. This is not a complete safety profile.
Stacking notes
See the dulaglutide entry. Combination with insulin or sulfonylureas raises hypoglycemia considerations.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Trulicity prescribing information · FDA prescribing information (2014)available via DailyMed; see dulaglutide entry
Track Trulicity (dulaglutide) in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.